NCT02426658View on ClinicalTrials.gov

Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

April 19, 2018

Study Completion Date

October 7, 2022

Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pemetrexed Disodium

Given IV

OTHER

Quality-of-Life Assessment

QOL studies

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT02426658 - Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | Biotech Hunter | Biotech Hunter